According to a recent LinkedIn post from Plenful, the company plans to participate in the NHIA 2026 conference focused on home infusion therapy. The post notes that Founder & CEO Joy Liu is scheduled to speak on how artificial intelligence may transform intake authorization workflows and improve operational efficiency.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that Plenful will exhibit at Booth #211, emphasizing AI-driven automation for workflows such as intake and processing, benefit verification, and prior authorization. The visibility at a specialized industry event could support customer acquisition in home infusion and pharmacy segments, potentially expanding the firm’s revenue pipeline.
The post suggests that Plenful is targeting complex, high-value administrative processes in infusion operations, positioning its platform as a workflow optimization tool. If the company succeeds in demonstrating measurable efficiency gains, it could strengthen its competitive position in healthcare IT and appeal to providers seeking cost reduction and throughput improvements.
As shared in the LinkedIn post, Plenful is also promoting on-site demos, which may help convert conference interest into qualified sales opportunities. For investors, increased engagement with decision-makers at NHIA could translate into longer-term contracts, deeper integrations, and a stronger foothold in the growing infusion therapy and pharmacy automation market.